Prescription Medicines
Telcardipine Tab. 80/5mg
- Product Category
- Complex hypertension treatment
- Active Ingredients
- Telmisartan, amlodipine
- Appearance
- A white or off-white, oblong tablet.
- Reimbursement Code
- 648105130
01 / 02
1. Composition and Strength : 1 tablet (280.0 mg) of this medicine
- Active ingredients:
Telmisartan (EP) · · · · · · · · 40.0mg
Amlodipine besylate (USP) · · · · · · · · 6.935mg (5mg as amlodipine)
- Additives: D-mannitol, magnesium aluminometasilicate, anhydrous calcium hydrogen phosphate, microcrystalline cellulose, sodium hydroxide, sodium stearyl fumarate, low-substituted hydroxypropyl cellulose, calcium carboxymethyl cellulose, colloidal silicon oxide, crospovidone, hypromellose
2. Effectiveness
Essential hypertension in which blood pressure is not adequately controlled with amlodipine or telmisartan monotherapy
3. Dosage and dosage
The recommended dosage of this medicine is 1 tablet once a day, which should be taken with water regardless of meals. If possible, it is recommended to take it at the same time every day (e.g. in the morning).
It is recommended to adjust the dose of each ingredient (telmisartan or amlodipine) before administering this medicine, but if blood pressure is not controlled for each ingredient as follows, you can consider switching to this medicine right away.
- 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg.
- 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or the 40/5 mg strength of this medicine.
- 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg.
- 80/10 mg: Administer 10 mg of amlodipine or 40/10 mg of this drug to patients whose blood pressure is not properly controlled.
For patients who are taking telmisartan and amlodipine in combination, they can switch to this drug (a combination drug with the same content of each active ingredient) for convenience of administration (limited to 40/5 mg and 80/10 mg of this drug).
• Patients with renal impairment: For patients with mild or moderate renal impairment, dose adjustment is not necessary, but for patients with severe renal impairment, it is recommended to start treatment with a low dose and gradually increase the dose. Additionally, periodic monitoring of serum potassium and creatinine levels is recommended. Telmisartan is not removed by hemodialysis.
• Patients with hepatic impairment: The daily dose of telmisartan for patients with mild or moderate hepatic impairment should not exceed 40 milligrams.
• Elderly: General amlodipine administration is recommended for the elderly, but caution must be taken when increasing the dose. (Refer to ‘3. Administer with caution to the following patients.’) For the elderly over 75 years of age, the clearance of amlodipine is reduced, so start treatment with a low dose and gradually increase the dose.
• Children: Administration of this drug is not recommended for pediatric patients under the age of 18 as its safety and efficacy have not been established. end.
4. Precautions for use
1. Warning
If drugs that act directly on the renin-angiotensin system, such as this drug, are administered to a pregnant woman, they may cause pathological conditions and death in the growing fetus or newborn. Use of these drugs, especially during the second and third trimesters of pregnancy, has been associated with fetal or neonatal harm, including hypotension, neonatal cranial hypoplasia, anuria, reversible or irreversible renal failure, and death. Oligohydramnios, which is believed to be caused by decreased renal function in the fetus, has been reported, and oligohydramnios is associated with limb spasms, craniofacial deformities, and pulmonary hypoplasia in the fetus. Prematurity, intrauterine growth retardation, and patent ductus arteriosus have been reported, but it is not clear whether this is due to exposure to this drug. If pregnancy is diagnosed, administration of this drug should be discontinued as soon as possible.
2. Do not administer to the following patients.
1) Patients with hypersensitivity to the main ingredient or dihydropyridine derivatives of this drug
2) Pregnant women (second and third trimester) or women who may be pregnant
3) Nursing mothers
4) Patients with biliary obstructive disease
5) Patients with severe liver impairment
6) Left ventricular outflow tract obstruction [e.g. [High grade aortic stenosis]
7) Patients with severe low blood pressure
8) Patients with shock (including cardiogenic shock)
9) Patients with hemodynamically unstable heart failure after acute myocardial infarction
10) Patients with genetic problems such as intolerance to the excipients of this drug
11) Combination use with aliskiren-containing preparations in patients with diabetes or moderate to severe renal impairment (glomerular filtration rate <60mL/min/1.73m2)
3. Administer with caution to the following patients:
1) Patients with primary aldosteronism
For patients with primary aldosteronism, antihypertensive drugs that inhibit the renin-angiotensin system are generally ineffective, so their use is not recommended.
2) Patients with arterial or mitral valve stenosis or obstructive hypertrophic cardiomyopathy
As with other vasodilators, particular caution should be used in patients with arterial or mitral valve stenosis or obstructive hypertrophic cardiomyopathy.
3) Patients with liver impairment
Amlodipine is extensively metabolized in the liver, and telmisartan is almost exclusively excreted in bile. Therefore, a decrease in liver clearance can be expected in patients with cholestasis, biliary obstructive disease, or hepatic impairment.
In patients with hepatic dysfunction, the half-life of amlodipine is prolonged and AUC values are higher (recommended dosing has not yet been established). Therefore, telmisartan should be administered with caution to patients with mild or moderate liver function impairment, and the dosage of telmisartan should not exceed 40 mg once a day.
4) Patients with gastrointestinal diseases such as active stomach or duodenal ulcer
Gastrointestinal adverse reactions occurred more frequently when telmisartan was administered than when placebo was administered. Gastrointestinal bleeding has been rarely observed in clinical trials, mostly occurring early in patients with gastrointestinal diseases. Therefore, caution should be exercised when administering this drug to patients with gastrointestinal diseases.
5) Patients with renovascular hypertension
When patients with bilateral renal artery stenosis or renal artery stenosis when only one kidney is functioning are treated with drugs that affect the renin-angiotensin-aldosterone system, the risk of severe hypotension or renal failure increases. When this drug is administered to patients with bilateral or unilateral renal artery stenosis, an increase in serum creatinine or blood uric acid nitrogen is expected, as is the case with angiotensin-converting enzyme (ACE) inhibitors.
6) Patients with renal failure requiring dialysis
7) Elderly people
Caution should be exercised when increasing the dose of amlodipine in elderly patients (see ‘Dosage/Dosage’ section).
8) Dual blockade of the renin-angiotensin-aldosterone system (RAAS): Concurrent use with other drugs that affect the renin-angiotensin-aldosterone system (RAAS), such as angiotensin receptor blockers (ARBs), ACE inhibitors, or aliskiren, is not recommended.
4. Adverse reactions
Safety Profile Summary
The most commonly reported adverse reactions are dizziness and peripheral edema, and the serious adverse reaction syncope may be reported rarely (less than 1 case per 1,000 patients).
The safety and tolerability of this drug were evaluated through five comparative trials involving more than 3,500 patients, of which more than 2,500 patients received the combination of telmisartan and amlodipine. In clinical trials, no additional adverse reactions were identified when telmisartan and amlodipine were coadministered compared to single adverse reactions. Peripheral edema, known as a dose-dependent adverse reaction to amlodipine single agent, was observed at an overall lower incidence in the amlodipine/telmisartan group than in patients who took amlodipine alone.
Although not observed during clinical trials or the post-marketing period, adverse reactions previously reported with single agents (telmisartan or amlodipine) may also be potential adverse reactions with this drug. For additional safety information, refer to the single-substance labeling for telmisartan or amlodipine.
Summary of adverse reactions
Adverse reactions reported in clinical trials or post-marketing experience of telmisartan/amlodipine combination drugs or single drugs (telmisartan or amlodipine) are classified according to MedDRA and shown in the table below.
The frequency of occurrence was defined as follows. Very common (≥1/10), common (≥1/100, <1/10), uncommon (≥1/1,000, <1/100), rare (≥1/10,000, <1/1,000), very rare (≤1/10,000), unknown (cannot be estimated from available data).
※ Table: Refer to attached document
Domestic post-marketing survey results
As a result of a post-marketing survey conducted on 610 people over 6 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 3.28% (20/610 people, 20 cases in total) regardless of causal relationship. Among these, the occurrence rate of serious adverse events was reported to be 0.49% (3/610 people, 3 cases in total), with hepatocellular carcinoma, cerebral infarction, and congestive heart failure each at 0.16% (1/610 people, 1 case). Serious adverse drug reactions for which a causal relationship with this drug cannot be ruled out were reported in 0.16% (1/610 people, 1 case in total), including congestive heart failure in 0.16% (1/610 people, 1 case).
The occurrence rate of unexpected adverse events was reported to be 1.31% (8/610 people, 8 cases in total) regardless of causal relationship, and 0.16% (1/610 people, 1 case) for hepatocellular carcinoma, musculoskeletal pain, cerebral infarction, neck pain, nasopharyngitis, epigastric discomfort, epigastric pain, and positional dizziness. Among these, the occurrence rate of unexpected adverse drug reactions for which a causal relationship with this drug cannot be ruled out was 0.33% (2/610 people, 2 cases in total), with 0.16% (1/610 people, 1 case) of epigastric discomfort and positional dizziness each reported.
5. General precautions
1) Pregnancy
Angiotensin II receptor antagonists should not be started during pregnancy. If continued treatment with angiotensin II receptor antagonists is not essential, patients planning pregnancy should substitute other antihypertensive agents with an established safety profile for use in pregnancy. If pregnancy is diagnosed, treatment with angiotensin II receptor antagonists should be discontinued as soon as possible and, if appropriate, treatment with another treatment should be initiated.
2) low blood pressure
In patients with an activated renin-angiotensin system, such as those with fluid or salt depletion (e.g., those receiving high-dose diuretics), symptomatic hypotension may occur after starting treatment with this drug. These conditions should be corrected before administering this drug or treatment should be initiated by reducing the dose of this drug under close medical supervision. If low blood pressure occurs, have the patient lie down and, if necessary, inject saline solution intravenously. Transient hypotensive reactions are not a contraindication to further treatment, and treatment can generally be continued without difficulty once blood pressure is stabilized.
3) Hyperkalemia
In the case of telmisartan, hyperkalemia may occur, especially in patients with renal impairment and/or heart failure, when being treated with other drugs that affect the renin-angiotensin-aldosterone system. Appropriate monitoring of serum potassium levels is recommended for patients at risk. Based on experience with the use of other drugs that affect the renin-angiotensin system, serum potassium levels may increase due to concurrent use with potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, and other drugs that can increase potassium levels (e.g. heparin), so co-administration of this drug with these drugs should be done with caution.
4) Patients with renal impairment
In the case of telmisartan, changes in renal function may be expected in sensitive patients as a result of inhibition of the renin-angiotensin-aldosterone system. In patients whose renal function may be dependent on the activity of the renin-angiotensin-aldosterone system (e.g., patients with severe congestive heart failure), treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and (rarely) acute renal failure and/or death. Similar results may occur in patients treated with telmisartan. When administering this drug to patients with renal impairment, periodic monitoring of serum potassium and creatinine levels is recommended. There is no experience with the use of this drug in patients who recently underwent kidney transplantation. Telmisartan is not removed by hemodialysis.
5) Increased risk of myocardial infarction or angina pectoris
In the case of amlodipine, an increase in the incidence, duration, and severity of angina pectoris or acute myocardial infarction has been documented in rare cases when calcium channel blocker therapy is initiated or the dose is increased, especially in patients with severe obstructive coronary artery disease. The mechanism for this effect has not yet been elucidated.
6) In the case of amlodipine, the plasma concentration half-life is long and a gradual blood pressure lowering effect appears even after discontinuation of administration. Therefore, when administering other antihypertensive drugs after discontinuation of administration, pay attention to the dosage and administration interval and administer carefully while observing the patient's condition.
7) Administration to heart failure patients
In the long-term, placebo-controlled trial of amlodipine in patients with severe heart failure (NYHA class III and IV) (PRAISE-2), the reported incidence of pulmonary edema was higher in the amlodipine group than in the placebo group. Therefore, it should be administered with caution to patients with heart failure.
Calcium channel blockers, including amlodipine, should be used with caution in patients with congestive heart failure because they may increase the risk of future cardiovascular events and death.
8) This medicine contains sorbitol, so it is not suitable for patients with genetic fructose intolerance.
9) Diabetes
For diabetic patients at additional risk for cardiovascular disease (e.g., patients with both diabetes and coronary artery disease), taking antihypertensive agents such as angiotensin II receptor antagonists or angiotensin-converting enzyme inhibitors may increase the risk of fatal myocardial infarction and unexpected death from cardiovascular disease. Since diabetic patients do not show symptoms of coronary artery disease and may not be diagnosed, an appropriate diagnostic evaluation (e.g. exercise stress test) to detect and treat coronary artery disease should be performed first when administering this drug to diabetic patients.
10) Effects on driving and machine operation
Although studies have not been conducted on the effect of this drug on driving and operating machinery, patients taking this drug should be careful when driving a car or operating dangerous machinery because drowsiness and dizziness may sometimes occur when taking antihypertensive drugs.
11) Ischemic heart disease
As with other antihypertensive drugs, excessive lowering of blood pressure in patients with ischemic heart disease or ischemic cardiovascular disease may cause myocardial infarction or stroke.
6. Interaction
1) No significant pharmacokinetic interaction was observed when amlodipine and telmisartan were used together. Studies have not been conducted on drug interactions between this drug and other medications.
2) Drug interactions of telmisartan
① Digoxin: When administered together with telmisartan and digoxin, an increase in the median highest plasma concentration (49%) and median lowest concentration (20%) of digoxin was observed. Therefore, it is recommended to monitor digoxin concentrations when starting, adjusting the dose, or discontinuing telmisartan to avoid excessive or under-digital action that may occur.
② Lithium: A reversible increase in serum lithium concentration and toxicity have been reported during concurrent administration of lithium and angiotensin-converting enzyme inhibitors. Such cases have also been reported with angiotensin receptor antagonists, including telmisartan. Therefore, monitoring serum lithium levels is recommended during concurrent use of lithium and telmisartan.
③ Ramipril and ramiprilat: In one clinical trial, the combined administration of telmisartan and ramipril increased the AUC0-24 and Cmax of ramipril and ramiprilat by 2.5 times. The clinical relevance of these observations is unknown.
④ Warfarin: Administration of telmisartan for 10 days slightly decreased the average trough plasma concentration of warfarin; This decrease did not cause a change in the International Normalized Ratio (INR).
⑤ Non-steroidal anti-inflammatory drugs (e.g., aspirin, COX-2 inhibitors, and non-steroidal anti-inflammatory drugs as anti-inflammatory therapy) may reduce the blood pressure lowering effect of angiotensin II receptor antagonists. In some patients with impaired renal function (e.g., dehydrated patients, elderly patients with impaired renal function), worsening renal function impairment, including acute renal failure (generally reversible), has been reported when coadministered with angiotensin II receptor antagonists and COX inhibitors. Therefore, co-administration should be done with caution, especially in elderly patients. Patients receiving a combination of non-steroidal anti-inflammatory painkillers and this drug should be provided with sufficient fluids, and renal function should be monitored periodically after starting the combination treatment.
⑥ Other drugs: There were no clinically significant interactions when telmisartan was administered in combination with acetaminophen, amlodipine, glibenclamide, simvastatin, hydrochlorothiazide, and ibuprofen. Telmisartan is not metabolized by the cytochrome P450 system and therefore has no effect on cytochrome P450 except for mild inhibition of CYP2C19 in vitro. Telmisartan is not expected to interact with drugs that inhibit cytochrome P450 enzymes. Except for the possibility of inhibiting the metabolism of drugs metabolized by CYP2C19, telmisartan is not expected to interact with drugs metabolized by cytochrome P450.
⑦ For additional drug interaction information, refer to the telmisartan single drug approval information.
⑧ Dual blockade of the renin-angiotensin-aldosterone system (RAAS) by co-administration of angiotensin receptor blockers (ARBs), ACE inhibitors, or aliskiren is associated with an increased risk of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy with these drugs. In patients receiving this drug concomitantly with other drugs that act on RAAS, blood pressure, renal function, and electrolytes should be closely monitored. Do not administer this drug and aliskiren-containing preparations together in patients with diabetes or moderate to severe renal impairment (glomerular filtration rate <60 mL/min/1.73m2).
3) Drug interactions with amlodipine
① In clinical trials, amlodipine was safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, nitroglycerin sublingual tablets, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral anti-diabetic agents.
② Grapefruit juice: When amlodipine is used in combination with grapefruit or grapefruit juice, the blood pressure lowering effect may increase in some patients due to increased bioavailability, so concurrent use is not recommended.
③ Cimetitine, sildenafil: There was no significant effect on the pharmacokinetics of amlodipine.
④ Atorvastatin, digoxin, warfarin: In clinical drug interaction studies, there was no pharmacokinetic effect due to amlodipine.
⑤ Simvastatin: As a result of multiple concurrent administration of 10 mg of amlodipine and 80 mg of simvastatin, exposure to simvastatin increased by 77% compared to when simvastatin was administered alone. Therefore, for patients taking amlodipine, simvastatin dosage is limited to a maximum of 20 mg per day.
⑥ Tacrolimus: There is a risk of increased blood concentration of tacrolimus when administered in combination with amlodipine, but the pharmacokinetic mechanism of this interaction is not fully understood. When amlodipine is administered to a patient receiving tacrolimus, the blood concentration of tacrolimus must be monitored and the tacrolimus dosage must be adjusted appropriately.
⑦ Cyclosporine: Drug interaction studies with cyclosporine and amlodipine have not been conducted in healthy volunteers or other populations, except in kidney transplant patients where variable trough concentration increases (average 0-40%) of cyclosporine were observed. In kidney transplant patients receiving amlodipine, monitoring of cyclosporine concentrations should be considered, and the cyclosporine dose should be reduced as needed.
⑧ CYP3A4 inhibitors: Coadministration of strong or moderate CYP3A4 inhibitors (protease inhibitors, azole antifungals, macrolides such as erythromycin or clarithromycin, verapamil or diltiazem) with amlodipine may significantly increase amlodipine exposure, resulting in an increased risk of hypotension. The clinical interpretation of these PK fluctuations may be more evident in older adults. Therefore, clinical monitoring and dose adjustment may be required.
⑨ CYP3A4 inducer: Co-administration with known CYP3A4 inducer may change the plasma concentration of amlodipine. Therefore, blood pressure should be monitored and dose adjustments considered, especially during and after co-administration with strong CYP3A4 inducers (e.g. rifampicin, hypericum perforatum).
⑩ Dantrolene (for injection): In animals, fatal ventricular fibrillation and cardiovascular collapse were observed in association with hyperkalemia after administration of verapamil and intravenous dantrolene. Because of the risk of hyperkalemia, it is recommended to avoid concomitant administration of calcium channel blockers such as amlodipine in patients susceptible to malignant hyperthermia and when managing malignant hyperthermia.
⑪ mTOR inhibitors: mTOR inhibitors (e.g. sirolimus, temsirolimus, everolimus) are substrates of CYP3A. Amlodipine is a weak CYP3A inhibitor, and when coadministered with mTOR inhibitors, amlodipine may increase exposure to mTOR inhibitors.
⑫ For additional drug interaction information, refer to the amlodipine single drug approval information.
7. Administration to pregnant and lactating women
1) Pregnant women: The use of angiotensin II receptor antagonists such as telmisartan is not recommended during the first three months of pregnancy and is prohibited during the second and third trimesters. There are no adequate data on the administration of this drug to pregnant women.
Non-clinical data showed no malformations, but fetal toxicity was observed. Exposure to angiotensin II receptor antagonists during the second and third trimesters of pregnancy causes human fetal toxicity (reduced renal function, amniotic fluid, delayed skull ossification) and neonatal toxicity (renal failure, hypotension, hyperkalemia).
Angiotensin II receptor antagonists should not be started during pregnancy. If continued treatment with angiotensin II receptor antagonists is not essential, patients planning pregnancy should substitute other antihypertensive agents with an established safety profile for use in pregnancy. If pregnancy is diagnosed, treatment with angiotensin II receptor antagonists should be discontinued as soon as possible and, if appropriate, treatment with another treatment should be initiated. If exposure to angiotensin II receptor antagonists has occurred since the second trimester of pregnancy, renal function and cranial ultrasound examination is recommended.
Infants of pregnant women who have taken angiotensin II receptor antagonists must be closely observed for the possibility of hypotension, frequent urination, and hyperkalemia.
The safety of amlodipine in pregnancy has not been established. Delayed and prolonged labor was observed in rats administered amlodipine at a dose equivalent to 50 times the maximum recommended human dose. In animal experiments, reproductive toxicity has been observed at high doses of amlodipine.
2) Lactating women: In human administration experience, it has been reported that amlodipine passes into human breast milk. It is not known whether telmisartan passes into human breast milk, but animal experiments have confirmed that telmisartan is secreted into breast milk. Therefore, this drug should not be administered while breastfeeding. (Refer to ‘2. Do not administer to the following patients’)
3) Reproductive function: The reproductive function of this drug and its individual active ingredients has not been studied in humans. A separate reproductive toxicity test was not conducted on co-administration of telmisartan and amlodipine. No effects of telmisartan on fertility in males and females were observed in nonclinical studies. Reversible biochemical changes in the sperm head have been reported in some patients receiving calcium channel blockers. There are insufficient clinical data regarding the potential effects of amlodipine on fertility. One rat study found detrimental effects on male fertility.
8. Administration to children
This drug is not recommended for use in pediatric patients under the age of 18 as there is insufficient data on its safety and effectiveness.
9. Administration to elderly people
No dose adjustment is necessary when administering this drug to the elderly, but it should be administered with caution as it cannot be ruled out that a more sensitive reaction may occur in some elderly patients. For elderly people over 75 years of age, the clearance of amlodipine is reduced, so start treatment at a low dose and gradually increase the dose.
10. Treatment in case of overdose
1) Telmisartan
There is limited information available on overdose in humans.
The most notable symptoms of telmisartan overdose were reported to be hypotension, tachycardia (due to parasympathetic stimulation), bradycardia, dizziness, and acute renal failure. If symptoms of low blood pressure appear, supportive treatment should be administered. Telmisartan is not removed by hemodialysis. Patients should be carefully observed, and symptomatic and supportive treatment should be administered depending on the time elapsed after taking the drug and the severity of symptoms. Emesis and/or gastric lavage may be considered. Medicinal charcoal may be useful for treatment. Serum electrolyte levels and creatinine levels should be monitored frequently. If hypotension occurs, the patient should be laid down and salt and fluid substitutes should be quickly supplied.
2) Amlodipine
Current data indicate that severe overdose may result in reflex tachycardia along with excessive peripheral vasodilation. In addition, it has been reported that symptoms of systemic hypotension are severe and persist for a long time, leading to a state of shock or resulting in fatal shock. When activated charcoal was administered to healthy volunteers immediately or up to 2 hours after administering 10 mg of amlodipine, the absorption of amlodipine was significantly reduced. In some cases, gastric lavage may be useful. Clinically serious hypotension caused by overdosage of amlodipine requires active support therapy for the cardiovascular system, such as frequent monitoring of heart and respiratory function, maintaining the position of the limbs higher than the body, and ensuring sufficient circulating fluids such as blood and urine excretion. Unless there are special cases where the use of vasoconstrictors is contraindicated, vasoconstrictors may be useful in restoring vascular tone and blood pressure. Intravenous administration of calcium gluconate may be useful in reversing the effects of calcium channel inhibitors. Because amlodipine has a very high protein binding rate, hemodialysis is not helpful and it is not removed by hemodialysis. Delayed non-cardiogenic pulmonary edema, which may occur 24 to 48 hours after amlodipine overdose, has been rarely reported and may require respiratory support therapy. Early resuscitative measures to maintain perfusion and cardiac output (including fluid overload) may be a trigger for non-cardiogenic pulmonary edema.
11. Storage and handling precautions
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
3) Due to the hygroscopic nature of the product, it must be opened and taken in a sealed blister immediately before administration.
12. Pharmaceutical equivalence test information Note 1
A. The test drug Twin Plus Tablets 80/5 mg (Withers Pharmaceuticals Co., Ltd.) and the control drug Twinstar Tablets 80/5 mg (Boehringer Ingelheim Korea Co., Ltd.) were administered orally as a single dose on an empty stomach to 48 healthy adults in a 2x2 crossover test. Amlodipine and telmisartan in the blood were measured, and the comparative evaluation items (AUCt, Cmax) were log-transformed and statistically processed. In this case, the 90% confidence interval of the mean difference was within log0.8 to log1.25, proving biological equivalence.
<Amlodipine>
※ Table: Refer to attached document
<Telmisartan>
※ Table: Refer to attached document
B. In accordance with Article 7, Paragraph 2 of the Pharmaceutical Equivalence Test Standards, the test drug Twin Plus Tablets 40/10,40/5mg (Withers Pharmaceuticals Co., Ltd.) submitted comparative dissolution test data with the reference drug Twin Plus Tablets 80/5mg (Withers Pharmaceuticals Co., Ltd.), and the dissolution pattern was equivalent to that of the reference drug. Accordingly, bioequivalence was proven with the relevant data.
Note 1. This drug was manufactured by Withers Pharmaceutical Co., Ltd. for all processes using the same raw materials as Twin Plus Tablets 80/5, 40/10, and 40/5 milligrams, using the same manufacturing method.
5. How to save
Store in a light-proof, airtight container at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle
7. Period of use
36 months from date of manufacture
- Active ingredients:
Telmisartan (EP) · · · · · · · · 40.0mg
Amlodipine besylate (USP) · · · · · · · · 6.935mg (5mg as amlodipine)
- Additives: D-mannitol, magnesium aluminometasilicate, anhydrous calcium hydrogen phosphate, microcrystalline cellulose, sodium hydroxide, sodium stearyl fumarate, low-substituted hydroxypropyl cellulose, calcium carboxymethyl cellulose, colloidal silicon oxide, crospovidone, hypromellose
2. Effectiveness
Essential hypertension in which blood pressure is not adequately controlled with amlodipine or telmisartan monotherapy
3. Dosage and dosage
The recommended dosage of this medicine is 1 tablet once a day, which should be taken with water regardless of meals. If possible, it is recommended to take it at the same time every day (e.g. in the morning).
It is recommended to adjust the dose of each ingredient (telmisartan or amlodipine) before administering this medicine, but if blood pressure is not controlled for each ingredient as follows, you can consider switching to this medicine right away.
- 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg.
- 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or the 40/5 mg strength of this medicine.
- 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg.
- 80/10 mg: Administer 10 mg of amlodipine or 40/10 mg of this drug to patients whose blood pressure is not properly controlled.
For patients who are taking telmisartan and amlodipine in combination, they can switch to this drug (a combination drug with the same content of each active ingredient) for convenience of administration (limited to 40/5 mg and 80/10 mg of this drug).
• Patients with renal impairment: For patients with mild or moderate renal impairment, dose adjustment is not necessary, but for patients with severe renal impairment, it is recommended to start treatment with a low dose and gradually increase the dose. Additionally, periodic monitoring of serum potassium and creatinine levels is recommended. Telmisartan is not removed by hemodialysis.
• Patients with hepatic impairment: The daily dose of telmisartan for patients with mild or moderate hepatic impairment should not exceed 40 milligrams.
• Elderly: General amlodipine administration is recommended for the elderly, but caution must be taken when increasing the dose. (Refer to ‘3. Administer with caution to the following patients.’) For the elderly over 75 years of age, the clearance of amlodipine is reduced, so start treatment with a low dose and gradually increase the dose.
• Children: Administration of this drug is not recommended for pediatric patients under the age of 18 as its safety and efficacy have not been established. end.
4. Precautions for use
1. Warning
If drugs that act directly on the renin-angiotensin system, such as this drug, are administered to a pregnant woman, they may cause pathological conditions and death in the growing fetus or newborn. Use of these drugs, especially during the second and third trimesters of pregnancy, has been associated with fetal or neonatal harm, including hypotension, neonatal cranial hypoplasia, anuria, reversible or irreversible renal failure, and death. Oligohydramnios, which is believed to be caused by decreased renal function in the fetus, has been reported, and oligohydramnios is associated with limb spasms, craniofacial deformities, and pulmonary hypoplasia in the fetus. Prematurity, intrauterine growth retardation, and patent ductus arteriosus have been reported, but it is not clear whether this is due to exposure to this drug. If pregnancy is diagnosed, administration of this drug should be discontinued as soon as possible.
2. Do not administer to the following patients.
1) Patients with hypersensitivity to the main ingredient or dihydropyridine derivatives of this drug
2) Pregnant women (second and third trimester) or women who may be pregnant
3) Nursing mothers
4) Patients with biliary obstructive disease
5) Patients with severe liver impairment
6) Left ventricular outflow tract obstruction [e.g. [High grade aortic stenosis]
7) Patients with severe low blood pressure
8) Patients with shock (including cardiogenic shock)
9) Patients with hemodynamically unstable heart failure after acute myocardial infarction
10) Patients with genetic problems such as intolerance to the excipients of this drug
11) Combination use with aliskiren-containing preparations in patients with diabetes or moderate to severe renal impairment (glomerular filtration rate <60mL/min/1.73m2)
3. Administer with caution to the following patients:
1) Patients with primary aldosteronism
For patients with primary aldosteronism, antihypertensive drugs that inhibit the renin-angiotensin system are generally ineffective, so their use is not recommended.
2) Patients with arterial or mitral valve stenosis or obstructive hypertrophic cardiomyopathy
As with other vasodilators, particular caution should be used in patients with arterial or mitral valve stenosis or obstructive hypertrophic cardiomyopathy.
3) Patients with liver impairment
Amlodipine is extensively metabolized in the liver, and telmisartan is almost exclusively excreted in bile. Therefore, a decrease in liver clearance can be expected in patients with cholestasis, biliary obstructive disease, or hepatic impairment.
In patients with hepatic dysfunction, the half-life of amlodipine is prolonged and AUC values are higher (recommended dosing has not yet been established). Therefore, telmisartan should be administered with caution to patients with mild or moderate liver function impairment, and the dosage of telmisartan should not exceed 40 mg once a day.
4) Patients with gastrointestinal diseases such as active stomach or duodenal ulcer
Gastrointestinal adverse reactions occurred more frequently when telmisartan was administered than when placebo was administered. Gastrointestinal bleeding has been rarely observed in clinical trials, mostly occurring early in patients with gastrointestinal diseases. Therefore, caution should be exercised when administering this drug to patients with gastrointestinal diseases.
5) Patients with renovascular hypertension
When patients with bilateral renal artery stenosis or renal artery stenosis when only one kidney is functioning are treated with drugs that affect the renin-angiotensin-aldosterone system, the risk of severe hypotension or renal failure increases. When this drug is administered to patients with bilateral or unilateral renal artery stenosis, an increase in serum creatinine or blood uric acid nitrogen is expected, as is the case with angiotensin-converting enzyme (ACE) inhibitors.
6) Patients with renal failure requiring dialysis
7) Elderly people
Caution should be exercised when increasing the dose of amlodipine in elderly patients (see ‘Dosage/Dosage’ section).
8) Dual blockade of the renin-angiotensin-aldosterone system (RAAS): Concurrent use with other drugs that affect the renin-angiotensin-aldosterone system (RAAS), such as angiotensin receptor blockers (ARBs), ACE inhibitors, or aliskiren, is not recommended.
4. Adverse reactions
Safety Profile Summary
The most commonly reported adverse reactions are dizziness and peripheral edema, and the serious adverse reaction syncope may be reported rarely (less than 1 case per 1,000 patients).
The safety and tolerability of this drug were evaluated through five comparative trials involving more than 3,500 patients, of which more than 2,500 patients received the combination of telmisartan and amlodipine. In clinical trials, no additional adverse reactions were identified when telmisartan and amlodipine were coadministered compared to single adverse reactions. Peripheral edema, known as a dose-dependent adverse reaction to amlodipine single agent, was observed at an overall lower incidence in the amlodipine/telmisartan group than in patients who took amlodipine alone.
Although not observed during clinical trials or the post-marketing period, adverse reactions previously reported with single agents (telmisartan or amlodipine) may also be potential adverse reactions with this drug. For additional safety information, refer to the single-substance labeling for telmisartan or amlodipine.
Summary of adverse reactions
Adverse reactions reported in clinical trials or post-marketing experience of telmisartan/amlodipine combination drugs or single drugs (telmisartan or amlodipine) are classified according to MedDRA and shown in the table below.
The frequency of occurrence was defined as follows. Very common (≥1/10), common (≥1/100, <1/10), uncommon (≥1/1,000, <1/100), rare (≥1/10,000, <1/1,000), very rare (≤1/10,000), unknown (cannot be estimated from available data).
※ Table: Refer to attached document
Domestic post-marketing survey results
As a result of a post-marketing survey conducted on 610 people over 6 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 3.28% (20/610 people, 20 cases in total) regardless of causal relationship. Among these, the occurrence rate of serious adverse events was reported to be 0.49% (3/610 people, 3 cases in total), with hepatocellular carcinoma, cerebral infarction, and congestive heart failure each at 0.16% (1/610 people, 1 case). Serious adverse drug reactions for which a causal relationship with this drug cannot be ruled out were reported in 0.16% (1/610 people, 1 case in total), including congestive heart failure in 0.16% (1/610 people, 1 case).
The occurrence rate of unexpected adverse events was reported to be 1.31% (8/610 people, 8 cases in total) regardless of causal relationship, and 0.16% (1/610 people, 1 case) for hepatocellular carcinoma, musculoskeletal pain, cerebral infarction, neck pain, nasopharyngitis, epigastric discomfort, epigastric pain, and positional dizziness. Among these, the occurrence rate of unexpected adverse drug reactions for which a causal relationship with this drug cannot be ruled out was 0.33% (2/610 people, 2 cases in total), with 0.16% (1/610 people, 1 case) of epigastric discomfort and positional dizziness each reported.
5. General precautions
1) Pregnancy
Angiotensin II receptor antagonists should not be started during pregnancy. If continued treatment with angiotensin II receptor antagonists is not essential, patients planning pregnancy should substitute other antihypertensive agents with an established safety profile for use in pregnancy. If pregnancy is diagnosed, treatment with angiotensin II receptor antagonists should be discontinued as soon as possible and, if appropriate, treatment with another treatment should be initiated.
2) low blood pressure
In patients with an activated renin-angiotensin system, such as those with fluid or salt depletion (e.g., those receiving high-dose diuretics), symptomatic hypotension may occur after starting treatment with this drug. These conditions should be corrected before administering this drug or treatment should be initiated by reducing the dose of this drug under close medical supervision. If low blood pressure occurs, have the patient lie down and, if necessary, inject saline solution intravenously. Transient hypotensive reactions are not a contraindication to further treatment, and treatment can generally be continued without difficulty once blood pressure is stabilized.
3) Hyperkalemia
In the case of telmisartan, hyperkalemia may occur, especially in patients with renal impairment and/or heart failure, when being treated with other drugs that affect the renin-angiotensin-aldosterone system. Appropriate monitoring of serum potassium levels is recommended for patients at risk. Based on experience with the use of other drugs that affect the renin-angiotensin system, serum potassium levels may increase due to concurrent use with potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, and other drugs that can increase potassium levels (e.g. heparin), so co-administration of this drug with these drugs should be done with caution.
4) Patients with renal impairment
In the case of telmisartan, changes in renal function may be expected in sensitive patients as a result of inhibition of the renin-angiotensin-aldosterone system. In patients whose renal function may be dependent on the activity of the renin-angiotensin-aldosterone system (e.g., patients with severe congestive heart failure), treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and (rarely) acute renal failure and/or death. Similar results may occur in patients treated with telmisartan. When administering this drug to patients with renal impairment, periodic monitoring of serum potassium and creatinine levels is recommended. There is no experience with the use of this drug in patients who recently underwent kidney transplantation. Telmisartan is not removed by hemodialysis.
5) Increased risk of myocardial infarction or angina pectoris
In the case of amlodipine, an increase in the incidence, duration, and severity of angina pectoris or acute myocardial infarction has been documented in rare cases when calcium channel blocker therapy is initiated or the dose is increased, especially in patients with severe obstructive coronary artery disease. The mechanism for this effect has not yet been elucidated.
6) In the case of amlodipine, the plasma concentration half-life is long and a gradual blood pressure lowering effect appears even after discontinuation of administration. Therefore, when administering other antihypertensive drugs after discontinuation of administration, pay attention to the dosage and administration interval and administer carefully while observing the patient's condition.
7) Administration to heart failure patients
In the long-term, placebo-controlled trial of amlodipine in patients with severe heart failure (NYHA class III and IV) (PRAISE-2), the reported incidence of pulmonary edema was higher in the amlodipine group than in the placebo group. Therefore, it should be administered with caution to patients with heart failure.
Calcium channel blockers, including amlodipine, should be used with caution in patients with congestive heart failure because they may increase the risk of future cardiovascular events and death.
8) This medicine contains sorbitol, so it is not suitable for patients with genetic fructose intolerance.
9) Diabetes
For diabetic patients at additional risk for cardiovascular disease (e.g., patients with both diabetes and coronary artery disease), taking antihypertensive agents such as angiotensin II receptor antagonists or angiotensin-converting enzyme inhibitors may increase the risk of fatal myocardial infarction and unexpected death from cardiovascular disease. Since diabetic patients do not show symptoms of coronary artery disease and may not be diagnosed, an appropriate diagnostic evaluation (e.g. exercise stress test) to detect and treat coronary artery disease should be performed first when administering this drug to diabetic patients.
10) Effects on driving and machine operation
Although studies have not been conducted on the effect of this drug on driving and operating machinery, patients taking this drug should be careful when driving a car or operating dangerous machinery because drowsiness and dizziness may sometimes occur when taking antihypertensive drugs.
11) Ischemic heart disease
As with other antihypertensive drugs, excessive lowering of blood pressure in patients with ischemic heart disease or ischemic cardiovascular disease may cause myocardial infarction or stroke.
6. Interaction
1) No significant pharmacokinetic interaction was observed when amlodipine and telmisartan were used together. Studies have not been conducted on drug interactions between this drug and other medications.
2) Drug interactions of telmisartan
① Digoxin: When administered together with telmisartan and digoxin, an increase in the median highest plasma concentration (49%) and median lowest concentration (20%) of digoxin was observed. Therefore, it is recommended to monitor digoxin concentrations when starting, adjusting the dose, or discontinuing telmisartan to avoid excessive or under-digital action that may occur.
② Lithium: A reversible increase in serum lithium concentration and toxicity have been reported during concurrent administration of lithium and angiotensin-converting enzyme inhibitors. Such cases have also been reported with angiotensin receptor antagonists, including telmisartan. Therefore, monitoring serum lithium levels is recommended during concurrent use of lithium and telmisartan.
③ Ramipril and ramiprilat: In one clinical trial, the combined administration of telmisartan and ramipril increased the AUC0-24 and Cmax of ramipril and ramiprilat by 2.5 times. The clinical relevance of these observations is unknown.
④ Warfarin: Administration of telmisartan for 10 days slightly decreased the average trough plasma concentration of warfarin; This decrease did not cause a change in the International Normalized Ratio (INR).
⑤ Non-steroidal anti-inflammatory drugs (e.g., aspirin, COX-2 inhibitors, and non-steroidal anti-inflammatory drugs as anti-inflammatory therapy) may reduce the blood pressure lowering effect of angiotensin II receptor antagonists. In some patients with impaired renal function (e.g., dehydrated patients, elderly patients with impaired renal function), worsening renal function impairment, including acute renal failure (generally reversible), has been reported when coadministered with angiotensin II receptor antagonists and COX inhibitors. Therefore, co-administration should be done with caution, especially in elderly patients. Patients receiving a combination of non-steroidal anti-inflammatory painkillers and this drug should be provided with sufficient fluids, and renal function should be monitored periodically after starting the combination treatment.
⑥ Other drugs: There were no clinically significant interactions when telmisartan was administered in combination with acetaminophen, amlodipine, glibenclamide, simvastatin, hydrochlorothiazide, and ibuprofen. Telmisartan is not metabolized by the cytochrome P450 system and therefore has no effect on cytochrome P450 except for mild inhibition of CYP2C19 in vitro. Telmisartan is not expected to interact with drugs that inhibit cytochrome P450 enzymes. Except for the possibility of inhibiting the metabolism of drugs metabolized by CYP2C19, telmisartan is not expected to interact with drugs metabolized by cytochrome P450.
⑦ For additional drug interaction information, refer to the telmisartan single drug approval information.
⑧ Dual blockade of the renin-angiotensin-aldosterone system (RAAS) by co-administration of angiotensin receptor blockers (ARBs), ACE inhibitors, or aliskiren is associated with an increased risk of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy with these drugs. In patients receiving this drug concomitantly with other drugs that act on RAAS, blood pressure, renal function, and electrolytes should be closely monitored. Do not administer this drug and aliskiren-containing preparations together in patients with diabetes or moderate to severe renal impairment (glomerular filtration rate <60 mL/min/1.73m2).
3) Drug interactions with amlodipine
① In clinical trials, amlodipine was safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, nitroglycerin sublingual tablets, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral anti-diabetic agents.
② Grapefruit juice: When amlodipine is used in combination with grapefruit or grapefruit juice, the blood pressure lowering effect may increase in some patients due to increased bioavailability, so concurrent use is not recommended.
③ Cimetitine, sildenafil: There was no significant effect on the pharmacokinetics of amlodipine.
④ Atorvastatin, digoxin, warfarin: In clinical drug interaction studies, there was no pharmacokinetic effect due to amlodipine.
⑤ Simvastatin: As a result of multiple concurrent administration of 10 mg of amlodipine and 80 mg of simvastatin, exposure to simvastatin increased by 77% compared to when simvastatin was administered alone. Therefore, for patients taking amlodipine, simvastatin dosage is limited to a maximum of 20 mg per day.
⑥ Tacrolimus: There is a risk of increased blood concentration of tacrolimus when administered in combination with amlodipine, but the pharmacokinetic mechanism of this interaction is not fully understood. When amlodipine is administered to a patient receiving tacrolimus, the blood concentration of tacrolimus must be monitored and the tacrolimus dosage must be adjusted appropriately.
⑦ Cyclosporine: Drug interaction studies with cyclosporine and amlodipine have not been conducted in healthy volunteers or other populations, except in kidney transplant patients where variable trough concentration increases (average 0-40%) of cyclosporine were observed. In kidney transplant patients receiving amlodipine, monitoring of cyclosporine concentrations should be considered, and the cyclosporine dose should be reduced as needed.
⑧ CYP3A4 inhibitors: Coadministration of strong or moderate CYP3A4 inhibitors (protease inhibitors, azole antifungals, macrolides such as erythromycin or clarithromycin, verapamil or diltiazem) with amlodipine may significantly increase amlodipine exposure, resulting in an increased risk of hypotension. The clinical interpretation of these PK fluctuations may be more evident in older adults. Therefore, clinical monitoring and dose adjustment may be required.
⑨ CYP3A4 inducer: Co-administration with known CYP3A4 inducer may change the plasma concentration of amlodipine. Therefore, blood pressure should be monitored and dose adjustments considered, especially during and after co-administration with strong CYP3A4 inducers (e.g. rifampicin, hypericum perforatum).
⑩ Dantrolene (for injection): In animals, fatal ventricular fibrillation and cardiovascular collapse were observed in association with hyperkalemia after administration of verapamil and intravenous dantrolene. Because of the risk of hyperkalemia, it is recommended to avoid concomitant administration of calcium channel blockers such as amlodipine in patients susceptible to malignant hyperthermia and when managing malignant hyperthermia.
⑪ mTOR inhibitors: mTOR inhibitors (e.g. sirolimus, temsirolimus, everolimus) are substrates of CYP3A. Amlodipine is a weak CYP3A inhibitor, and when coadministered with mTOR inhibitors, amlodipine may increase exposure to mTOR inhibitors.
⑫ For additional drug interaction information, refer to the amlodipine single drug approval information.
7. Administration to pregnant and lactating women
1) Pregnant women: The use of angiotensin II receptor antagonists such as telmisartan is not recommended during the first three months of pregnancy and is prohibited during the second and third trimesters. There are no adequate data on the administration of this drug to pregnant women.
Non-clinical data showed no malformations, but fetal toxicity was observed. Exposure to angiotensin II receptor antagonists during the second and third trimesters of pregnancy causes human fetal toxicity (reduced renal function, amniotic fluid, delayed skull ossification) and neonatal toxicity (renal failure, hypotension, hyperkalemia).
Angiotensin II receptor antagonists should not be started during pregnancy. If continued treatment with angiotensin II receptor antagonists is not essential, patients planning pregnancy should substitute other antihypertensive agents with an established safety profile for use in pregnancy. If pregnancy is diagnosed, treatment with angiotensin II receptor antagonists should be discontinued as soon as possible and, if appropriate, treatment with another treatment should be initiated. If exposure to angiotensin II receptor antagonists has occurred since the second trimester of pregnancy, renal function and cranial ultrasound examination is recommended.
Infants of pregnant women who have taken angiotensin II receptor antagonists must be closely observed for the possibility of hypotension, frequent urination, and hyperkalemia.
The safety of amlodipine in pregnancy has not been established. Delayed and prolonged labor was observed in rats administered amlodipine at a dose equivalent to 50 times the maximum recommended human dose. In animal experiments, reproductive toxicity has been observed at high doses of amlodipine.
2) Lactating women: In human administration experience, it has been reported that amlodipine passes into human breast milk. It is not known whether telmisartan passes into human breast milk, but animal experiments have confirmed that telmisartan is secreted into breast milk. Therefore, this drug should not be administered while breastfeeding. (Refer to ‘2. Do not administer to the following patients’)
3) Reproductive function: The reproductive function of this drug and its individual active ingredients has not been studied in humans. A separate reproductive toxicity test was not conducted on co-administration of telmisartan and amlodipine. No effects of telmisartan on fertility in males and females were observed in nonclinical studies. Reversible biochemical changes in the sperm head have been reported in some patients receiving calcium channel blockers. There are insufficient clinical data regarding the potential effects of amlodipine on fertility. One rat study found detrimental effects on male fertility.
8. Administration to children
This drug is not recommended for use in pediatric patients under the age of 18 as there is insufficient data on its safety and effectiveness.
9. Administration to elderly people
No dose adjustment is necessary when administering this drug to the elderly, but it should be administered with caution as it cannot be ruled out that a more sensitive reaction may occur in some elderly patients. For elderly people over 75 years of age, the clearance of amlodipine is reduced, so start treatment at a low dose and gradually increase the dose.
10. Treatment in case of overdose
1) Telmisartan
There is limited information available on overdose in humans.
The most notable symptoms of telmisartan overdose were reported to be hypotension, tachycardia (due to parasympathetic stimulation), bradycardia, dizziness, and acute renal failure. If symptoms of low blood pressure appear, supportive treatment should be administered. Telmisartan is not removed by hemodialysis. Patients should be carefully observed, and symptomatic and supportive treatment should be administered depending on the time elapsed after taking the drug and the severity of symptoms. Emesis and/or gastric lavage may be considered. Medicinal charcoal may be useful for treatment. Serum electrolyte levels and creatinine levels should be monitored frequently. If hypotension occurs, the patient should be laid down and salt and fluid substitutes should be quickly supplied.
2) Amlodipine
Current data indicate that severe overdose may result in reflex tachycardia along with excessive peripheral vasodilation. In addition, it has been reported that symptoms of systemic hypotension are severe and persist for a long time, leading to a state of shock or resulting in fatal shock. When activated charcoal was administered to healthy volunteers immediately or up to 2 hours after administering 10 mg of amlodipine, the absorption of amlodipine was significantly reduced. In some cases, gastric lavage may be useful. Clinically serious hypotension caused by overdosage of amlodipine requires active support therapy for the cardiovascular system, such as frequent monitoring of heart and respiratory function, maintaining the position of the limbs higher than the body, and ensuring sufficient circulating fluids such as blood and urine excretion. Unless there are special cases where the use of vasoconstrictors is contraindicated, vasoconstrictors may be useful in restoring vascular tone and blood pressure. Intravenous administration of calcium gluconate may be useful in reversing the effects of calcium channel inhibitors. Because amlodipine has a very high protein binding rate, hemodialysis is not helpful and it is not removed by hemodialysis. Delayed non-cardiogenic pulmonary edema, which may occur 24 to 48 hours after amlodipine overdose, has been rarely reported and may require respiratory support therapy. Early resuscitative measures to maintain perfusion and cardiac output (including fluid overload) may be a trigger for non-cardiogenic pulmonary edema.
11. Storage and handling precautions
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
3) Due to the hygroscopic nature of the product, it must be opened and taken in a sealed blister immediately before administration.
12. Pharmaceutical equivalence test information Note 1
A. The test drug Twin Plus Tablets 80/5 mg (Withers Pharmaceuticals Co., Ltd.) and the control drug Twinstar Tablets 80/5 mg (Boehringer Ingelheim Korea Co., Ltd.) were administered orally as a single dose on an empty stomach to 48 healthy adults in a 2x2 crossover test. Amlodipine and telmisartan in the blood were measured, and the comparative evaluation items (AUCt, Cmax) were log-transformed and statistically processed. In this case, the 90% confidence interval of the mean difference was within log0.8 to log1.25, proving biological equivalence.
<Amlodipine>
※ Table: Refer to attached document
<Telmisartan>
※ Table: Refer to attached document
B. In accordance with Article 7, Paragraph 2 of the Pharmaceutical Equivalence Test Standards, the test drug Twin Plus Tablets 40/10,40/5mg (Withers Pharmaceuticals Co., Ltd.) submitted comparative dissolution test data with the reference drug Twin Plus Tablets 80/5mg (Withers Pharmaceuticals Co., Ltd.), and the dissolution pattern was equivalent to that of the reference drug. Accordingly, bioequivalence was proven with the relevant data.
Note 1. This drug was manufactured by Withers Pharmaceutical Co., Ltd. for all processes using the same raw materials as Twin Plus Tablets 80/5, 40/10, and 40/5 milligrams, using the same manufacturing method.
5. How to save
Store in a light-proof, airtight container at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle
7. Period of use
36 months from date of manufacture
Product Updates
Total 1items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 1 | Telcardipine Tab. 80/5mg | Precautions for use | 2026.02.12 | PDF0248_201907930_Precautions for use_Telcardipine 80/5mg.pdf |